Racial/ethnic disparities in ART adherence in the United States: Findings from the MACH14 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 5, 2012, Pages 466-472

  Simoni, Jane M ^a   Huh, David ^a   Wilson, Ira B ^b   Shen, Jie ^c   Goggin, Kathy ^d   Reynolds, Nancy R ^e   Remien, Robert H ^f   Rosen, Marc I ^g   Bangsberg, David R ^h   Liu, Honghu ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e YALE UNIVERSITY   (United States)

^f Columbia University ^*  (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antiretroviral treatment; HIV AIDS; medication adherence; race ethnicity

Indexed keywords

COCAINE; DIAMORPHINE; OPIATE; PSYCHEDELIC AGENT; SEDATIVE AGENT;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; DEMOGRAPHY; DEPRESSION; ETHNIC OR RACIAL ASPECTS; ETHNICITY; FEMALE; GENDER; HEALTH CARE SYSTEM; HUMAN; INCOME; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE; RISK; SUBSTANCE ABUSE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84864284810     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825db0bd     Document Type: Article

References (43)

1. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058. (Pubitemid 34499429)
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
3. Hartzell JD, Spooner K, Howard R, et al. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007;44:411-416. (Pubitemid 46555375)
4. Halkitis PN, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDS. 2008;22:323-335. (Pubitemid 351562967)
5. Halkitis PN, Parsons JT, Wolitski RJ, et al. Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care. 2003;15:89-102. (Pubitemid 36135378)
6. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18:683-688. (Pubitemid 38393468)
7. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82-92. (Pubitemid 32115053)
8. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45:1377-1385. (Pubitemid 351411918)
9. Pence BW, Ostermann J, Kumar V, et al. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:194-201. (Pubitemid 351172186)
10. Sullivan PS, Campsmith ML, Nakamura GV, et al. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One. 2007;2:e552.
11. Silverberg MJ, Leyden W, Quesenberry CP Jr, et al. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24:1065-1072.
12. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr. 2009;52:290-293.
13. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009; 21:976-983.
14. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381. (Pubitemid 34626108)
15. Harzke AJ, Williams ML, Nilsson-Schönnesson L, et al. Psychosocial factors associated with adherence to antiretroviral medications in a sample of HIV-positive African American drug users. AIDS Care. 2004;16:458-470. (Pubitemid 38651063)
16. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56:146-150.
17. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728. (Pubitemid 32717795)
18. Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002; 30:401-409. (Pubitemid 34857314)
19. Lewis-Fernández R, Das AK, Alfonso C, et al. Depression in US Hispanics: diagnostic and management considerations in family practice. J Am Board Fam Pract. 2005;18:282-296. (Pubitemid 41663999)
20. Gonzalez JS, Hendriksen ES, Collins EM, et al. Latinos and HIV/AIDS: examining factors related to disparity and identifying opportunities for psychosocial intervention research. AIDS Behav. 2009;13: 582-602.
21. Thrasher AD, Earp JAL, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84-93.
22. Waldrop-Valverde D, Osborn CY, Rodriguez A, et al. Numeracy skills explain racial differences in HIV medication management. AIDS Behav. 2010;14:799-806.
23. Liu H, Wilson IB, Goggin K, et al. MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav. 2012; in press.
24. Cohen J, Cohen, Patricia, et al. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Mahwah: Psychology Press; 2003.
25. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II (BDI-II). San Antonio, TX: Psychological Corporation; 1996.
26. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
27. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385.
28. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med. 1983;13:595-605. (Pubitemid 13019024)
29. Rogers WH, Wilson IB, Bungay KM, et al. Assessing the performance of a new depression screener for primary care (PC-SAD). J Clin Epidemiol. 2002;55:164-175. (Pubitemid 34051530)
30. Anastasi A. Psychological Testing. 6th ed. New York: Macmillan; 1988.
31. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011; 42:352-360.
32. Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: Evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82(suppl 1):S71-79. (Pubitemid 43850179)
33. Papke LE, Wooldridge JM. Econometric methods for fractional response variables with an application to 401 (k) plan participation rates. J Appl Econ. 1996;11:619-632.
34. Huh D, Flaherty BP, Simoni JM. Optimizing the analysis of adherence interventions using logistic generalized estimating equations. AIDS Behav. 2012;16:422-431.
35. Sue DW, Capodilupo CM, Torino GC, et al. Racial microaggressions in everyday life: Implications for clinical practice. Am Psychol. 2007;62: 271-286.
36. Myers HF. Ethnicity-and socio-economic status-related stresses in context: an integrative review and conceptual model. J Behav Med. 2008;32: 9-19.
37. Bird ST, Bogart LM, Delahanty DL. Health-related correlates of perceived discrimination in HIV care. AIDS Patient Care STDS. 2004;18: 19-26. (Pubitemid 38435509)
38. Bogart LM, Wagner GJ, Galvan FH, et al. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African-American men with HIV. Ann Behav Med. 2010;40:184-190.
39. Saha S, Sanders DS, Korthuis PT, et al. The role of cultural distance between patient and provider in explaining racial/ethnic disparities in HIV care. Patient Educ Couns. 2011;85:e278-e284.
40. Kripalani S, Weiss BD. Teaching about health literacy and clear communication. J Gen Intern Med. 2006;21:888-890. (Pubitemid 44024939)
41. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:267-273. (Pubitemid 29226671)
42. Osborn CY, Paasche-Orlow MK, Davis TC, et al. Health literacy: an overlooked factor in understanding HIV health disparities. Am J Prev Med. 2007;33:374-378. (Pubitemid 47575812)
43. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African Americans with HIV. J Acquir Immune Defic Syndr. 2009;53: 648-655.